Search results
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via AOL· 5 days agoIn the first quarter of the year, Moderna reported $167 million in sales of its only product on the...
Moderna Reports Smaller Than Expected Q1 Loss, Prepares For RSV Vaccine And Spikevax 2024-2025...
Benzinga via Yahoo Finance· 5 days agoThursday, Moderna Inc (NASDAQ:MRNA) reported a first-quarter EPS loss of $(3.07), down from an...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 5 days agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 5 days agoModerna stock soared on Thursday after its first-quarter earnings report sailed past Wall Street’s...
Moderna posts quarterly sales beat, smaller loss than expected
Reuters via Yahoo Finance· 5 days ago(Reuters) -Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came...
Decoding Moderna Inc (MRNA): A Strategic SWOT Insight
GuruFocus.com via Yahoo Finance· 3 days agoStrengths Robust mRNA Technology Platform: Moderna Inc (NASDAQ:MRNA) has established a strong...
Moderna expects CDC to view its RSV vaccine as equal to rival shots
Reuters· 5 days ago, opens new tab said on Thursday it expects U.S. Center for Disease Control and Prevention (CDC)...
Why Moderna Stock Blasted 13% Higher Today
Motley Fool via Yahoo Finance· 5 days agoModerna (NASDAQ: MRNA) was a fine stock to heal an ailing portfolio on the second-to-last trading day of the week. The company, which developed and sells...
Moderna Swings to 1Q Loss, But Sees Data on New Vaccine Later in '24
Market Watch· 5 days agoModerna swung to a hefty first-quarter loss but the maker of Covid 19 vaccines forecast some seasonal strength in ...
Moderna (NASDAQ:MRNA) PT Raised to $106.00
ETF DAILY NEWS· 12 hours agoModerna (NASDAQ:MRNA – Free Report) had its price target increased by Canaccord Genuity Group from $91.00 to $106.00 in a report published on Friday, Benzinga reports. Canaccord ...
